Total Valuation
Nascent Biotech has a market cap or net worth of $51.66K. The enterprise value is -$197.96K.
Market Cap$51.66K
Enterprise Value-$197.96K
Share Statistics
Nascent Biotech has 172,842,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding172,842,670
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nascent Biotech’s return on equity (ROE) is 8.13 and return on invested capital (ROIC) is 1662.02%.
Return on Equity (ROE)8.13
Return on Assets (ROA)-3.78
Return on Invested Capital (ROIC)1662.02%
Return on Capital Employed (ROCE)8.69
Revenue Per Employee0.00
Profits Per Employee-1.04M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nascent Biotech is ―. Nascent Biotech’s PEG ratio is 0.31.
PE Ratio―
PS Ratio0.00
PB Ratio-109.22
Price to Fair Value-109.22
Price to FCF-23.64
Price to Operating Cash Flow-0.04
PEG Ratio0.31
Income Statement
In the last 12 months, Nascent Biotech had revenue of 0.00 and earned -2.09M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-320.00K
Operating Income-2.23M
Pretax Income-2.09M
Net Income-2.09M
EBITDA527.43K
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.35M and capital expenditures -2.00, giving a free cash flow of -1.35M billion.
Operating Cash Flow-1.35M
Free Cash Flow-1.35M
Free Cash Flow per Share>-0.01
Dividends & Yields
Nascent Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta55.80
52-Week Price Change700.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)68.74
Average Volume (3m)66.98K
Important Dates
Nascent Biotech upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Nascent Biotech as a current ratio of 0.68, with Debt / Equity ratio of -47.73%
Current Ratio0.68
Quick Ratio0.68
Debt to Market Cap<0.01
Net Debt to EBITDA-0.47
Interest Coverage Ratio-5.79
Taxes
In the past 12 months, Nascent Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nascent Biotech EV to EBITDA ratio is 52.68, with an EV/FCF ratio of -23.43.
EV to Sales0.00
EV to EBITDA52.68
EV to Free Cash Flow-23.43
EV to Operating Cash Flow-23.43
Balance Sheet
Nascent Biotech has $47.39K in cash and marketable securities with $59.00K in debt, giving a net cash position of -$11.61K billion.
Cash & Marketable Securities$47.39K
Total Debt$59.00K
Net Cash-$11.61K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nascent Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―